Coma following ECT and intravenous droperidol: case report.

Area of Science:

• Neuroscience
• Pharmacology
• Psychiatry

Background:

• Electroconvulsive therapy (ECT) is a treatment for severe mental health conditions.
• Agitation can occur as a side effect of ECT.
• Droperidol is a medication sometimes used to manage agitation.

Observation:

• A 60-year-old male with psychotic depression became comatose after intravenous droperidol administration.
• The droperidol was given to treat delirious agitation following ECT.
• This adverse event prompted a review of potential causes and drug effects.

Findings:

• The differential diagnosis included neuroleptic malignant syndrome.
• A unique detrimental effect of droperidol in the context of post-ECT delirium was considered.
• The patient's coma suggests a severe adverse reaction to droperidol in this specific clinical scenario.

Implications:

• Recent literature supports droperidol for severe agitation.
• This case underscores the need for caution when using droperidol for post-ECT delirium.
• Further research may be needed to clarify the safety profile of droperidol in this context.